LifeScan

What LifeScan does

LifeScan is a global medical device company that manufactures and markets blood glucose monitoring (BGM) systems and digital diabetes management solutions under the OneTouch brand. Founded in 1981 and headquartered in Malvern, Pennsylvania, the company serves an installed base of more than 20 million consumers across 50+ countries through its portfolio of Bluetooth-connected meters (OneTouch Verio Reflect and Verio Flex), proprietary Verio test strips, lancing devices (OneTouch Delica Plus), and two companion mobile apps: the consumer-facing OneTouch Reveal and the coaching-oriented OneTouch Reveal Plus (powered by Welldoc's FDA-authorized BlueStar digital therapeutic). The technology stack combines Bluetooth-connected hardware, mobile applications with pattern detection and Blood Sugar Mentor guidance features, and integrations with Apple Health, Google Health Connect, and activity trackers.

LifeScan generates revenue primarily through the recurring sale of proprietary test strips consumed by patients using its meters, supplemented by hardware sales of meters and lancing devices, enterprise direct purchasing accounts (minimum $400,000 annual commitment, $2,500 minimum order), authorized US pharmaceutical wholesaler distribution (AmerisourceBergen, Cardinal Health, McKesson, Henry Schein), retail pharmacy, and direct-to-consumer e-commerce via OneTouch.com. The company also derives subscription-style revenue from OneTouch Reveal Plus, which is offered through health benefit plans. Go-to-market is multi-channel: enterprise field sales to healthcare providers and institutions, consumer e-commerce, and channel partnerships with distributors globally, supported by clinical evidence publications, participation at ATTD and ADA Scientific Sessions, and the LifeScan Diabetes Institute education platform.

The company has been in significant transition: it was acquired by Platinum Equity from Johnson & Johnson in 2018 for approximately $2.1 billion at a 2017 revenue base of $1.5 billion, filed for Chapter 11 in July 2025, emerged in December 2025 under majority ownership of lenders Canyon Partners and Brigade Capital Management after eliminating 75%+ of prepetition debt, appointed Jonathan Salkin as permanent CEO in May 2026, and announced a transformational partnership with i-SENS in February 2026 to launch the OneTouch Vita continuous glucose monitoring (CGM) system in Europe by early 2027.

Name

LifeScan

Legal name

LifeScan Enterprises LLC

Website

https://lifescan.com

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

LifeScan manufactures and markets OneTouch-branded blood glucose monitoring systems, including Bluetooth-connected meters, test strips, and digital coaching apps, serving over 20 million diabetes patients across 50+ countries via retail, pharmacy, and D2C channels.

Ownership category

akta.pro rank

Product category

Blood Glucose Monitoring and Diabetes Management Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

akta.pro secondary industries

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)

Keywords

• Blood glucose monitoring
• Diabetes management devices
• Continuous glucose monitoring
• Digital health coaching
• Medical device manufacturing

Headquarters

HQ city

Malvern

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Blood Glucose Monitoring Hardware: Sale of OneTouch blood glucose meters and lancing devices. One-time hardware purchases by consumers, healthcare providers, and institutions.
2. Test Strip Consumables: Recurring revenue from proprietary OneTouch test strips required for glucose meters. Creates recurring revenue stream as strips are consumable supplies used regularly by patients.
3. Digital Health Applications: Revenue from OneTouch Reveal Plus app with premium coaching features, potentially through subscription or per-user licensing models with health benefit plans.
4. Health Benefit Plan Coverage: OneTouch Reveal Plus available through health benefit plans for adults with diabetes, suggesting reimbursement and payer coverage revenue model.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

LifeScan manufactures and markets blood glucose monitoring systems under the OneTouch brand, including Bluetooth-connected meters (OneTouch Verio Reflect, OneTouch Verio Flex), proprietary test strips, and lancing devices. These hardware products are paired with companion mobile apps (OneTouch Reveal and OneTouch Reveal Plus) that provide pattern detection, in-app coaching, and healthcare provider data sharing, and the company is expanding into continuous glucose monitoring through the i-SENS-partnered OneTouch Vita CGM System.

Product overview

LifeScan is a global leader in blood glucose monitoring and diabetes management, offering a comprehensive portfolio of products and services organized around the OneTouch brand. The core offering consists of Bluetooth-connected blood glucose meters — the OneTouch Verio Reflect (with Blood Sugar Mentor guidance technology) and OneTouch Verio Flex — used with OneTouch Verio test strips and the OneTouch Delica Plus lancing device. These meters sync via Bluetooth with two companion mobile apps: the OneTouch Reveal app (pattern detection, data sharing, and alerts) and the OneTouch Reveal Plus (powered by Welldoc's BlueStar digital therapeutic, adding individualized coaching, insulin calculation, and meal planning). LifeScan distributes these products globally through retail, pharmacy, and its direct-to-consumer online store. The company is expanding into continuous glucose monitoring through the upcoming OneTouch Vita CGM System, developed in partnership with i-SENS and targeted for European launch in 2027. LifeScan also operates the LifeScan Diabetes Institute for professional and patient education.

Differentiator

Problem solved

Functional benefit

Brands

• OneTouch Verio Reflect: Smart blood glucose meter with Blood Sugar Mentor technology that provides real-time guidance and personalized feedback
• OneTouch Verio Flex
• OneTouch Reveal App
• OneTouch Reveal Plus

Products and services

• OneTouch Verio Reflect Bluetooth-connected blood glucose monitoring meter featuring Blood Sugar Mentor real-time guidance technology and ColorSure Dynamic Range Indicator, providing personalized insight, guidance, and encouragement based on blood glucose results for people with diabetes.
• OneTouch Verio Flex Bluetooth-connected blood glucose monitoring meter that syncs with the OneTouch Reveal mobile app, used extensively in LifeScan's real-world evidence studies demonstrating glycemic control improvements in people with Type 1 and Type 2 diabetes.
• OneTouch Verio Test Strips Proprietary blood glucose test strips used with OneTouch Verio meters for self-monitoring of blood glucose, forming the recurring consumables component of LifeScan's core BGM offering.
• OneTouch Delica Plus Lancing Device Lancing device used for blood glucose testing, designed for ease of use and patient comfort during finger-stick blood sampling.
• OneTouch Reveal Mobile App Mobile diabetes management app that syncs with OneTouch Verio meters via Bluetooth, automatically tracking blood glucose results and other health information, providing pattern detection alerts, and enabling data sharing with healthcare providers and caregivers.
• OneTouch Reveal Plus Mobile App Advanced mobile diabetes management app powered by Welldoc's BlueStar FDA-authorized digital therapeutic, providing individualized real-time in-app coaching, meal planning support, insulin calculator, activity tracker connectivity, and blood pressure and weight management features for adults with diabetes. Available to health benefit plans for adults 18 and older living with diabetes.
• OneTouch Vita CGM System Continuous glucose monitoring (CGM) system under development by LifeScan in partnership with i-SENS, leveraging i-SENS's advanced biosensor technology. Represents LifeScan's expansion beyond traditional blood glucose monitoring into the CGM segment.

Quantifiable outcome

• A1c reduction of 1% in Type 2 diabetes patients using OneTouch Reveal app with Bluetooth connected meter after 3 months
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• i-SENScoreStrategic or Co-development Partner · 11 February 2026Transformational partnership to launch continuous glucose monitoring (CGM) system under OneTouch Vita brand. Combines LifeScan's trusted OneTouch brand and global distribution network with i-SENS's advanced biosensor technology and manufacturing capabilities. Products to launch in Germany, Ireland, Portugal, and Belgium by early 2027 before expanding to additional markets. This is a significant milestone enabling LifeScan to enter the CGM market after 40+ years in glucose monitoring.
• Willis Towers WatsonminorGTM or Marketing Partner · 1 October 2019Partnership to expand access to OneTouch Reveal Plus, a cost-effective diabetes digital coaching solution, through Willis Towers Watson's employer and benefits consulting relationships.
• Sanvita MedicalminorChannel Partner/ Reseller/ Distributor · 21 May 2019Agreement to market and distribute Continuous Glucose Monitoring (CGM) devices, expanding LifeScan's product portfolio beyond traditional blood glucose monitoring.
• WelldoccoreTechnology or Integration · 9 April 2019Partnership to power OneTouch Reveal Plus mobile app with Welldoc's BlueStar technology. Provides evidence-based in-app coaching, individualized real-time feedback based on patient's specific treatment plan, meal planning support, insulin calculator, and connectivity with activity trackers. First digital therapeutic approved by FDA for adults with type 2 diabetes.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Insulet: Insulet's Omnipod tubeless insulin patch pump targets the same Type 1 and insulin-intensive Type 2 diabetes patients as OneTouch. It is a relevant adjacent competitor as LifeScan expands its diabetes portfolio beyond BGM.
• Medtronic Diabetes: Medtronic operates an integrated diabetes business spanning CGM (Guardian), insulin pumps, and closed-loop systems. It competes with LifeScan for the same patient population and increasingly the same digital ecosystem, although its core is pump-centric rather than BGM-centric.
• Tandem Diabetes Care: Tandem is a leading insulin pump maker with the t:slim X2 and Tandem Mobi products, integrated with Dexcom CGM. It targets the same insulin-requiring diabetes population as LifeScan's OneTouch franchise and represents the pump-based competitive set LifeScan's CGM will need to integrate with.

Direct peers

• Abbott Diabetes Care: Abbott's FreeStyle Libre franchise is the dominant CGM globally and a major BGM competitor. Abbott competes head-to-head with LifeScan's OneTouch in glucose monitoring hardware, test strips, and increasingly in connected digital diabetes management.
• Roche Diabetes Care: Roche's Accu-Chek is one of the largest BGM brands worldwide and a direct competitor to OneTouch meters and strips. Roche also sells insulin pumps and digital diabetes tools, making it a broad incumbent in the same category as LifeScan.
• Ascensia Diabetes Care: Ascensia (Contour portfolio, spun out of Bayer) is a focused BGM competitor with overlapping retail and pharmacy distribution, similar BGM-plus-strip economics, and direct overlap with OneTouch on the provider recommendation and pharmacy shelf.
• Dexcom: Dexcom is the leading standalone continuous glucose monitoring (CGM) company, and the principal competitor LifeScan will face as it enters CGM through the i-SENS partnership. Both companies target people with diabetes, generate recurring revenue from disposable sensors, and increasingly compete for the same prescriber and payer relationships.

Emerging players

• Senseonics: Senseonics develops the Eversense implantable long-term CGM, an emerging CGM technology that competes in the same CGM category LifeScan is entering. As a small-cap, single-product player, it is comparable in scale to where LifeScan's CGM business is likely to be at launch.

Regional players

• Ypsomed: Ypsomed sells the mylife Diabetes Care portfolio of BGM, insulin pumps, and infusion sets, primarily in Europe. It is a direct BGM competitor in the same European markets where LifeScan plans to launch OneTouch Vita CGM in 2027.

Others

• Welldoc: Welldoc powers LifeScan's OneTouch Reveal Plus app with its BlueStar FDA-authorized digital therapeutic. It is a direct technology partner of LifeScan and a relevant peer in the diabetes digital health and dose-decision-support category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/OneTouch
• LinkedInlinkedin.com/company/lifescan

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeScan